|Print This Page Email to a Friend|
Dr. William Gerthoffer, professor and chair of biochemistry and molecular biology at the University of South Alabama College of Medicine, presented at the 2015 NanoBio Summit at the University of Alabama at Birmingham in Birmingham, Ala., on Oct. 15-16, 2015, and at the Celsion-EGEN annual research meeting in New York on Oct. 27, 2015.
Dr. Gerthoffer’s presentations described a new drug delivery system developed by an Alabama biotechnology company, Celsion-EGEN in Huntsville, Ala., which can be used to target lung diseases including pulmonary hypertension, asthma and lung cancers. “New drugs might be developed that treat these diseases, which in some individuals are not treatable with current drugs,” Dr. Gerthoffer said.
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.
“Scientists from several Alabama universities and biotechnology companies attended these conferences and heard about advances in drug delivery being made here at USA,” Dr. Gerthoffer said.
A webcast of the Celsion-EGEN annual research meeting is available at http://investor.celsion.com/events.cfm.
© 2018 USA Health